SRR1797254
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.380
- ANGIOGENESIS+0.210
- PEROXISOME+0.160
- MYC_TARGETS_V1+0.150
- P53_PATHWAY+0.130
- TGF_BETA_SIGNALING+0.120
- GLYCOLYSIS+0.100
- NOTCH_SIGNALING+0.100
- PI3K_AKT_MTOR_SIGNALING+0.090
- DNA_REPAIR+0.040
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.390
- KRAS_SIGNALING_UP-0.350
- COMPLEMENT-0.250
- INTERFERON_GAMMA_RESPONSE-0.250
- MITOTIC_SPINDLE-0.220
- ALLOGRAFT_REJECTION-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
- ANDROGEN_RESPONSE-0.190
- PANCREAS_BETA_CELLS-0.190
- G2M_CHECKPOINT-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R31 | — | — | 0.694 |
| 2 | DRR168539 | — | — | 0.688 |
| 3 | SRR12202489 | — | — | 0.680 |
| 4 | DRR168523 | — | — | 0.666 |
| 5 | R98 | — | — | 0.665 |
| 6 | MDT-AP-1100 | Med | Medulloblastoma | 0.664 |
| 7 | R176 | — | — | 0.664 |
| 8 | R100 | — | — | 0.659 |
| 9 | TCGA-DK-A1AG-01A-11R-A13Y-07 | — | — | 0.659 |
| 10 | GSM5359423 | — | — | 0.658 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.210 | Remibrutinib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.130 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.040 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |